These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38012576)

  • 1. Clinical efficacy and safety of tigecycline based on therapeutic drug monitoring for carbapenem-resistant Gram-negative bacterium pneumonia in intensive care units.
    Bai XR; Wang ZZ; Li WC; Wang YG; Lou R; Qu X; Fan L; Zhang W; Wu YC; Yan SY; Zhang L
    BMC Infect Dis; 2023 Nov; 23(1):830. PubMed ID: 38012576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tigecycline Therapy for Nosocomial Pneumonia due to Carbapenem-Resistant Gram-Negative Bacteria in Critically Ill Patients Who Received Inappropriate Initial Antibiotic Treatment: A Retrospective Case Study.
    Wu X; Zhu Y; Chen Q; Gong L; Lin J; Lv D; Feng J
    Biomed Res Int; 2016; 2016():8395268. PubMed ID: 28044137
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparable Efficacy of Tigecycline versus Colistin Therapy for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Pneumonia in Critically Ill Patients.
    Kim WY; Moon JY; Huh JW; Choi SH; Lim CM; Koh Y; Chong YP; Hong SB
    PLoS One; 2016; 11(3):e0150642. PubMed ID: 26934182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes in patients infected with carbapenem-resistant Acinetobacter baumannii and treated with tigecycline alone or in combination therapy.
    Guner R; Hasanoglu I; Keske S; Kalem AK; Tasyaran MA
    Infection; 2011 Dec; 39(6):515-8. PubMed ID: 21789524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens.
    Chen Z; Shi X
    Medicine (Baltimore); 2018 Sep; 97(38):e12467. PubMed ID: 30235740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tigecycline-based versus sulbactam-based treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex.
    Ye JJ; Lin HS; Yeh CF; Wu YM; Huang PY; Yang CC; Huang CT; Lee MH
    BMC Infect Dis; 2016 Aug; 16():374. PubMed ID: 27496018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the ratio of the estimated area under the concentration-time curve to minimum inhibitory concentration (estimated AUIC) as a predictor of the outcome for tigecycline treatment for pneumonia due to multidrug-resistant bacteria in an intensive care unit.
    Xu Y; Jin L; Liu N; Luo X; Dong D; Tang J; Wang Y; You Y; Liu Y; Chen M; Yu Z; Hao Y; Gu Q
    Int J Infect Dis; 2019 May; 82():79-85. PubMed ID: 30878630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
    Liang CA; Lin YC; Lu PL; Chen HC; Chang HL; Sheu CC
    Clin Microbiol Infect; 2018 Aug; 24(8):908.e1-908.e7. PubMed ID: 29108947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulbactam combined with tigecycline improves outcomes in patients with severe multidrug-resistant Acinetobacter baumannii pneumonia.
    Deng Y; Chen L; Yue M; Huang X; Yang Y; Yu H
    BMC Infect Dis; 2022 Oct; 22(1):795. PubMed ID: 36271362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of tigecycline in the treatment of infections caused by carbapenem-resistant gram-negative bacteria in pediatric liver transplant recipients: A retrospective study.
    Chen F; Shen C; Pang X; Zhang Z; Deng Y; Han L; Chen X; Zhang J; Xia Q; Qian Y
    Transpl Infect Dis; 2020 Feb; 22(1):e13199. PubMed ID: 31627248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidrug-resistant Gram-negative infections: what are the treatment options?
    Giamarellou H; Poulakou G
    Drugs; 2009 Oct; 69(14):1879-901. PubMed ID: 19747006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the efficacies of three empirically-selected antibiotics for treating Acinetobacter baumannii pulmonary infection: experience from a teaching hospital in China

.
    Li P; Wang X; Wang W; Zhao X
    Int J Clin Pharmacol Ther; 2017 Jul; 55(7):588-593. PubMed ID: 28291507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Excess Mortality Associated With Colistin-Tigecycline Compared With Colistin-Carbapenem Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Bacteremia: A Multicenter Prospective Observational Study.
    Cheng A; Chuang YC; Sun HY; Sheng WH; Yang CJ; Liao CH; Hsueh PR; Yang JL; Shen NJ; Wang JT; Hung CC; Chen YC; Chang SC
    Crit Care Med; 2015 Jun; 43(6):1194-204. PubMed ID: 25793437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [[The profile of antibiotic resistantpathogens isolated from ascites fluid patients in intensive care unit during past 12 years].
    Kong Q; Hu L; Zhou Z; Shen J; Xu X; Ye Y; Zhang Z; Li J
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2016 Mar; 28(3):211-6. PubMed ID: 29916671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is tigecyclin a good choice in the treatment of multidrug-resistant Acinetobacter baumannii pneumonia?
    Tasbakan MS; Pullukcu H; Sipahi OR; Tasbakan MI; Aydemir S; Bacakoglu F
    J Chemother; 2011 Dec; 23(6):345-9. PubMed ID: 22233818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis.
    Chuang YC; Cheng CY; Sheng WH; Sun HY; Wang JT; Chen YC; Chang SC
    BMC Infect Dis; 2014 Feb; 14():102. PubMed ID: 24564226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro Interactions of Antibiotic Combinations of Colistin, Tigecycline, and Doripenem Against Extensively Drug-Resistant and Multidrug-Resistant Acinetobacter baumannii.
    Park GC; Choi JA; Jang SJ; Jeong SH; Kim CM; Choi IS; Kang SH; Park G; Moon DS
    Ann Lab Med; 2016 Mar; 36(2):124-30. PubMed ID: 26709259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia.
    Khawcharoenporn T; Pruetpongpun N; Tiamsak P; Rutchanawech S; Mundy LM; Apisarnthanarak A
    Int J Antimicrob Agents; 2014 Apr; 43(4):378-82. PubMed ID: 24613422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria.
    De Pascale G; Montini L; Pennisi M; Bernini V; Maviglia R; Bello G; Spanu T; Tumbarello M; Antonelli M
    Crit Care; 2014 May; 18(3):R90. PubMed ID: 24887101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.